ASPG and Hyperglycemia: However, pediatric patients undergoing cancer treatment should be evaluated with serial blood glucose assessments for potential risk of hyperglycemia, particularly patients aged over 10 years and those with Down syndrome, CNS involvement, obesity, or planned therapy that includes glycemic-altering agents such as GCS and asparaginase [12].